Pathogenesis of rheumatoid arthritis and c-Fos/AP-1

Cell Cycle

Volumn 8, Issue 10, 2009, Pages 1539-1543

  Shiozawa, Shunichi ^a,b,c,d   Tsumiyama, Ken ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c Investigator of the Center of Excellence (COE)   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

c Fos AP 1; Inflammatory cytokine; Joint destruction; Matrix metalloproteinase; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROTEIN C FOS; RECOMBINANT INTERLEUKIN 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

CELL CYCLE REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL CYCLE; HUMANS; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1;

EID: 66849143692     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.10.8411     Document Type: Review

References (111)

1. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072:129-157
2. Karin M, Liu Z-G, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-246 (Pubitemid 27135992)
3. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated transacting factor. Cell 1987; 49:729-739 (Pubitemid 18094763)
4. Schonthal A, Herrlich P, Rahmsdorf HJ, Ponta H. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell 1988; 54:325-334
5. Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990; 9:2241-2246 (Pubitemid 20198968)
6. Shiozawa S, Tanaka Y, Fujita T, Tokuhisa T. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992; 148:3100-3104
7. Kuroki Y, Shiozawa S, Sugimoto T, Fujita T. Constitutive expression of c-fos gene inhibits type 1 collagen synthesis in transfected osteoblasts. Biochem Biophys Res Commun 1992; 182:1389-1394
8. Miyauchi A, Kuroki Y, Fukase M, Fujita T, Chihara K, Shiozawa S. Persistent expression of proto-oncogene c-fos stimulates osteoclast differentiation. Biochem Biophys Res Commun 1994; 205:1547-1555
9. Shiozawa S, Shimizu S, Tanaka K, Hino K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997; 99:1210-1216 (Pubitemid 27142756)
10. Kawasaki H, Komai K, Ouyang Z, Murata M, Hikasa M, Ohgiri M, et al. c-Fos/activator protein-1 transactivates wee1 kinase at G1/S to inhibit premature mitosis in antigen-specific Th1 cells. EMBO J 2001; 20:4618-4627 (Pubitemid 32772054)
11. Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z, Nakashima T, et al. Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003; 22:6839-6844 (Pubitemid 37386682)
12. Sirum-Connolly K, Brinckerhoff C. Interleukin-1 or phorbol induction of the stromelysin promoter requires an element that cooperates with AP-1. Nucleic Acids Res 1991; 19:335-341 (Pubitemid 21896978)
13. Hess J, Porte D, Munz C, Angel P. AP-1 and Cbfa/Runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast- specific element 2/AP-1 composite element. J Biol Chem 2001; 276:20029-20038 (Pubitemid 37411071)
14. Sun Y, Wenger L, Brinckerhoff CE, Misra RR, Cheung HS. Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1 metalloproteinase 1 pathway. J Biol Chem 2002; 277:1544-1552
15. Milner JM, Patel A, Rowan AD. Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum 2008; 58:3644-3656
16. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinase: role in arthritis. Front Biosci 2006; 11:529-543
17. Shiozawa S, Shiozawa K, Fujita T. Morphologic observations in the early phase of the cartilage-pannus junction. Arthritis Rheum 1983; 26:472-478
18. Fassbender HG. Is pannus a residue of inflammation? Arthritis Rheum 1984; 27:956-957
19. Shiozawa S, Tanaka Y, Fujita T, Tokuhisa T. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992; 148:3100-3104
20. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Fassbender HG, Gay S. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol Int 1992; 12:53-59
21. Asahara H, Fujisawa K, Kobata T, Hasunuma T, Maeda T, Asanuma M, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997; 40:912-918 (Pubitemid 27200009)
22. Aicher WK, Heer AH, Trabandt A, Bridges SL Jr, Schroeder HW Jr, Stransky G, et al. Overexpression of zinc-finger transcription factor Z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. J Immunol 1994; 152:5940-5948 (Pubitemid 24174176)
23. Wakisaka S, Suzuki N, Takeno M, Takeba Y, Nagafuchi H, Saito N, et al. Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell outgrowth in patients with rheumatoid arthritis. Ann Rheum Dis 1998; 57:487-497 (Pubitemid 28428219)
24. Pope RM, Lovis R, Mungre S, Perlman H, Koch AE, Haines III GK. C/EBP beta in rheumatoid arthritis: correlation with inflammation, not disease specificity. Clin Immunol 1999; 91:271-282 (Pubitemid 29250213)
25. Jacobs RA, Perrett D, Axon JM, Herbert KE, Scott DL. Rheumatoid synovial cell proliferation, transformation and fibronectin secretion in culture. Clin Exp Rheumatol 1995; 13:717-723 (Pubitemid 26016999)
26. Schaser K, Kinne RW, Beil H, Kladny B, Stoss H. Proliferation of T-cells, macrophages, neutrophilic granulocytes and fibroblast-like cells in the synovial membrane of patients with rheumatoid arthritis. Verh Dtsch Ges Pathol 1996; 80:276-280
27. Fassbender HG. Joint destruction in various arthritic diseases. In: Kuettner K, et al. eds. Articular cartilage biochemistry. New York: Raven Press 1986; 371-389
28. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985; 28:25-31. (Pubitemid 15193018)
29. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008; 58:2936-2948
30. Dayer J-M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003; 42:3-10. (Pubitemid 37220894)
31. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant IL-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990; 49:238-245 (Pubitemid 20140749)
32. Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75:306-310 (Pubitemid 19074265)
33. Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, et al. Distinct roles of matrix metalloproteinases in the early- and late-phase development of neuropathic pain. Nat Med 2008; 14:331-336
34. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999; 42:1109-1118 (Pubitemid 29268947)
35. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008; 26:817-823
36. Van den Berg WB. Lessons from animal models of arthritis. Curr Rheumatol Rep 2002; 4:232-239
37. Joosten LAB, Helsen MMA, Saxne T, van De Loo FAJ, Heinegard D, van Den Berg D. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNFα blockade only ameliorates joint destruction. J Immunol 1999; 163:5049-5055 (Pubitemid 29501273)
38. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in IL-1 receptor antagonist-deficient mice. J Exp Med 2000; 191:313-320 (Pubitemid 30060920)
39. Chikanza IC, Roux-Lombrad P, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995; 38:64-68
40. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial fluid. Ann Rheum Dis 1992; 51:731-734
41. Koch AE, Kunkel SL, Chensue SW, Haines GK, Streiter RM. Expression of interleukin- 1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992; 65:23-29
42. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interlukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2:706-708 (Pubitemid 18217356)
43. Rooney M, Symons JA, Duff GW. Interlukin-1β in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990; 10:217-219
44. Smolen JS, Van Der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from ASPIRE trial. Arthritis Rheum 2006; 54:702-710
45. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363:675-681 (Pubitemid 38296553)
46. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-conrolled, 52-week trial. Arthritis Rheum 2004; 50:1400-1411 (Pubitemid 38608061)
47. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602 (Pubitemid 32162982)
48. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35-45. (Pubitemid 36091645)
49. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354:1932-1939.
50. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher LH, et al. A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1 and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol Cell Biol 2000; 20:6084-6094 (Pubitemid 30613056)
51. Finnegan A, Doodes PD. Pathways for interleukin-1-driven arthritis. Arthritis Rheum 2008; 58:3282-3285
52. Ventura J-J, Kennedy NJ, Lamb JA, Flavell RA, Davis RJ. c-Jun NH2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell Biol 2003; 23:2871-2882 (Pubitemid 36403084)
53. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008; 58:3461-3470
54. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-286
55. Reunanan N, Li S-P, Ahonen M, Foschi M, Han J, Kahari V-M. Activation of p38α MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002; 277:32360-32368 (Pubitemid 34969054)
56. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211:19-26. (Pubitemid 46363892)
57. Ray A, Bal BS, Ray BK. Transcriptional induction of matrix metalloproteinase-9 in the chondrocyte and synoviocyte cells is regulated via a novel mechanism: evidence for functional cooperation between serum amyloid A-activating factor-1 and AP-1. J Immunol 2005; 175:4039-4048 (Pubitemid 41292067)
58. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med 2007; 13:156-163 (Pubitemid 46245765)
59. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441:235-238
60. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-β induces development of the Th17 lineage. Nature 2006; 441:231-234
61. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-189 (Pubitemid 43214587)
62. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-970 (Pubitemid 29215007)
63. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol 2000; 164:2832-2838 (Pubitemid 30115519)
64. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-1352 (Pubitemid 29218305)
65. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cell 2005; 19:180-184
66. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7:784-795
67. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNFα, by human macrophages. J Immunol 1998; 160:3513-3521 (Pubitemid 28164746)
68. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593-2603 (Pubitemid 26193037)
69. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811-821 (Pubitemid 26091152)
70. Chaubaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12:1092-1099 (Pubitemid 30479493)
71. Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P, et al. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. J Rheumatol 2002; 29:1262-1272 (Pubitemid 34601964)
72. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002; 61:704-713 (Pubitemid 34787708)
73. Koenders MI, Joosten LAB, van der Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 3:29-33. (Pubitemid 44629098)
74. Van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Lowik CW. Interleukin-17 synergises with tumour necrosis factor α to induce cartilage breakdown in vitro and in vivo. Ann Rheum Dis 2002; 61:870-876
75. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100:5986-5990 (Pubitemid 36576918)
76. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum 2004; 50:650-659 (Pubitemid 38198849)
77. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58:3710-3719
78. Horai R, Nakajima A, Habiro K, Kotani M, Nakae S, Matsuki T, et al. TNFα is crucial for the development fo autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004; 114:1603-1611 (Pubitemid 40385551)
79. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002; 169:3345-3352 (Pubitemid 35013184)
80. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, et al. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 2008; 181:329-337
81. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005; 52:1960-1967 (Pubitemid 40994316)
82. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779-1785 (Pubitemid 39488063)
83. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin- 6 induction. Immunity 2008; 29:628-636
84. Yang E, Lerner L, Besser D, Darnell E Jr. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 2003; 278:15794-15799 (Pubitemid 36799693)
85. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54:158-168 (Pubitemid 43122198)
86. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54:2817-2829 (Pubitemid 44497760)
87. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-1167 (Pubitemid 47309731)
88. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008; 371:987-997
89. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63:1062-1068 (Pubitemid 39120355)
90. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43:1001-1009 (Pubitemid 30368176)
91. Zwerina J, Redlich K, Polzer K, Joosten L, Krönke G, Distler J, et al. TNF-induced structural joint damage is mediated by interleukin-1. Proc Natl Acad Sci USA 2007; 104:11742-11747 (Pubitemid 47175083)
92. Braddock M, Quinn A. Targeting IL-1 inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discovery 2004; 3:1-10. (Pubitemid 38499760)
93. Pap T, Gay S, Schett G. Matrix metalloproteinases. In: Smolen JS, Lipsky PE, editors. Biological therapies in rheumatology. (London): Taylor & Francis Ltd 2002; 483-497
94. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162:2163-2168 (Pubitemid 16149701)
95. Van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001; 3:18-26. (Pubitemid 32223802)
96. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000; 43:2143-2151
97. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant IL-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990; 49:238-245 (Pubitemid 20140749)
98. Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75:306-310 (Pubitemid 19074265)
99. Probert T, Plows D, Kontogeorgos G, Kollias G. The type I IL-1 receptor acts in series with TNFα to induce arthritis in TNFα transgenic mice. Eur J Immunol 1995; 25:1794-1797
100. Shiozawa S, Shiozawa K, Fujita T. Presence of HLA-DR antigen on synovial type A and B cells: an immunoelectron microscopic study in rheumatoid arthritis, osteoarthritis and normal traumatic joints. Immunology 1983; 50:587-594 (Pubitemid 14246902)
101. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Ishikawa H, Hirohata K, et al. The restoration of proliferation and differentiation of peripheral blood mononuclear non-adherent cells into immunoglobulin-secreting cells by autologous synovial adherent cells from patients with rheumatoid arthritis. Virchow Arch B Cell Pathol 1988; 54:350-356 (Pubitemid 18090469)
102. Klareskog L, Forsum U, Kabelitz D, et al. Immune functions of human synovial cells: phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 1982; 25:488-501.
103. Kuroki Y, Shiozawa S, Yoshihara R, Hotta T. The contribution of human c-fos DNA to cultured synovial cells: a transfection study. J Rheumatol 1993; 20:422-428 (Pubitemid 23102462)
104. Shimizu K, Kawasaki H, Morisawa T, et al. Spontaneous and cytokine regulated c-fos gene expression in rheumatoid synovial cells: resistance to cytokine stimulation when the c-fos gene is overexpressed. Ann Rheum Dis 2000; 59:636-640 (Pubitemid 30617090)
105. Mudgett JS, et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998; 41:110-121 (Pubitemid 28041929)
106. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995; 269:403-407
107. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355:704-712 (Pubitemid 44244541)
108. Teitelbaum SL. RANKing c-Jun in osteoclast development. J Clin Invest 2004; 114:463-465 (Pubitemid 39572093)
109. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-mediated joint destruction. J Clin Invest 2002; 110:1419-1427 (Pubitemid 35396913)
110. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191:275-286 (Pubitemid 30060917)
111. Hashiramoto A, Yamane T, Tsumiyama K, et al. Biological clock modulates arthritis. Submitted.